Pancreatic adenocarcinoma therapeutics markets, share, size, growth, trend & forecast to 2019

Pancreatic Adenocarcinoma Therapeutics Markets, Share, Size, Growth, Trend & Forecast to 2019: Radiant Insights, Inc Summary GBI Research, the leading business intelligence provider, has released its latest research,'Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant', which provides in-depth analysis of pancreatic adenocarcinoma market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-showsdiversity-of-novel-targets-though-commercial-impact-remains-distant The global pancreatic adenocarcinoma therapeutics market is expected to grow from approximately $856m in 2012 to $1.2 billion in 2019, with growth driven by small changes in multiple factors. These include the impact of the drugs approved in the forecast period, but also the increase in the prevalence of the disease and minor improvements in diagnostics that result in more patients being eligible for pharmacological.

Scope - A brief introduction to pancreatic adenocarcinoma, including the disease's pathogenesis, risk factors, diagnosis, staging and treatment algorithms for each stage.

- In-depth analysis of drugs available for the treatment of pancreatic adenocarcinoma, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.

- Comprehensive review of the pipeline for pancreatic adenocarcinoma therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period.

The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, program type.

- Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.

- Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.

- Discussion of the drivers and barriers for market growth.

- Discussion of the licensing and co-development deals landscape in pancreatic adenocarcinoma, Includes an analysis of licensing deals by stage of development, molecule type and mechanism of action. Also includes an analysis of both licensing and co-development deals by year and value and network maps of licensing and co-development deals.

Reasons to buy - Understand the vast Scope and diversity of the pipeline, including which molecule types and mechanisms of action are prominent.

- Observe the trends in clinical trial duration and size amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for pancreatic adenocarcinoma therapeutics.

- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the pancreatic adenocarcinoma therapeutics market.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-showsdiversity-of-novel-targets-though-commercial-impact-remains-distant Table of Contents Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 8 2 Introduction 9 2.1 Overview 9 2.1.1 Pancreatic Neuroendocrine Tumors 10 2.2 Pathophysiology 11 2.2.1 Inherited Disease 11 2.2.2 Somatic Mutations 11 2.3 Signs and Symptoms 12 2.4 Risk Factors 13 2.4.1 Smoking 13 2.4.2 Pancreatitis and Other Medical Conditions 13

2.4.3 Obesity 13 2.4.4 Infections 13 2.5 Diagnosis 13 2.6 Treatment Algorithm 14 2.6.1 Surgery 14 2.6.2 Radiation Therapy 14 2.6.3 Chemotherapy 15 2.6.4 Algorithm of Chemotherapeutic Treatment for Pancreatic Cancer 16 Read Complete Report with TOC @ http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-showsdiversity-of-novel-targets-though-commercial-impact-remains-distant 3 Marketed Products 33 3.1 Approved Products 33 3.1.1 Gemcitabine 33 3.1.2 IV Fluorouracil 34 3.1.3 Tarceva 34 3.1.4 Abraxane 35 3.1.5 Teysuno/TS-1 36 3.2 Off-Label Products 36 3.2.1 Xeloda 36 3.2.2 Eloxatin 37 3.3 Marketed Products - Discussion 37 4 Product Pipeline 39 4.1 Pipeline Overview 39 4.2 Overview of Pipeline by Phase, Route of Administration, Molecule Type and Molecular Target 39 4.3 Key Trends in Drug Development within the Pancreatic Cancer Pipeline 44 4.3.1 Enhancing Drug Delivery 44

4.3.2 Targeted Therapies 44 4.3.3 Immunotherapy 45 4.4 Clinical Trial Duration and Size 47 4.5 Clinical Trial Failure Rate 50 4.6 Clinical Trial Discussion 51 4.7 Promising Drug Candidates in Pipeline 53 4.7.1 Masivet/Kinavet (US) - AB Science 53 4.7.2 Glufosfamide - Eleison Pharmaceuticals Incorporated 54 4.7.3 Tertomotide - Kael-GemVax Co., Ltd 55 4.7.4 TH-302 - Threshold Pharmaceuticals 56 4.7.5 HyperAcute Pancreas - NewLink Genetics Corporation 58 4.7.6 MM-398 - Merrimack Pharmaceuticals Inc. 60 4.8 Pipeline Discussion 62 Read Complete Report with TOC @ http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-showsdiversity-of-novel-targets-though-commercial-impact-remains-distant 5 Market Forecast 67 5.1 Introduction 67 5.2 Global Market 67 5.3 North America 70 5.3.1 Treatment Usage Patterns 70 5.3.2 Annual Cost of Therapy 71 5.3.3 Market Size 73 5.4 Top Five European Countries 75 5.4.1 Treatment Usage Patterns 75 5.5 Annual Cost of Therapy 77 5.6 Market Size 79

5.7 Japan 81 5.7.1 Treatment Usage Patterns 81 5.7.2 Annual Cost of Therapy 82 5.7.3 Market Size 82 5.8 Drivers and Barriers 83 5.8.1 Drivers 83 5.8.2 Barriers 84 Read Complete Report with TOC @ http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-showsdiversity-of-novel-targets-though-commercial-impact-remains-distant 6 Deals 87 6.1 Licensing Deals 87 6.1.1 Clavis Enters Licensing and Development Agreement with Clovis 89 6.1.2 Baxter Enters Licensing Agreement with Onconova for Rigosertib 90 6.1.3 Lorus Therapeutics Enters Into Licensing Agreement with Zor Pharma 90 6.1.4 Novogen Enters Into Licensing Agreement with Marshall Edwards For NV-196 And NV-143 90 6.2 Co-Development Deals 90 6.2.1 Merck Serono Enters Into Co-Development Agreement with Threshold Pharma for TH-302 92 7 Appendix 93 7.1 All Pipeline Drugs by Phase 93 7.1.1 Discovery 93 7.1.2 Preclinical 95 7.1.3 IND/CTA-Filed 103 7.1.4 Phase I 103 7.1.5 Phase II 105 7.1.6 Phase III 110 7.1.7 Pre-Registration 111

7.2 Market Forecasts to 2019 111 7.2.1 Global 111 7.2.2 US 112 7.2.3 Canada 112 7.2.4 UK 113 7.2.5 France 113 7.2.6 Germany 114 7.2.7 Italy 114 7.2.8 Spain 115 7.2.9 Japan 115 7.3 Abbreviations 116 7.4 References 117 7.5 Methodology 122 7.6 Secondary Research 122 7.7 Contact Us 122 7.8 Disclaimer 122 Read Complete Report with TOC @ http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-showsdiversity-of-novel-targets-though-commercial-impact-remains-distant List of Tables Table 1: Pancreatic Cancer Therapeutics, Inherited Cancer Syndromes Associated with an Increased Risk of Pancreatic Cancer 11 Table 2: Pancreatic Cancer Therapeutics, Common Mutations in Pancreatic Cancer 12 Table 3: Pancreatic Cancer Therapeutics, Tumor Staging in Pancreatic Cancer 14 Table 4: Pancreatic Cancer Therapeutics, ECOG Performance Status Scores and Description 15 Table 5: Pancreatic Cancer Therapeutics, Common Endpoints in Oncology Clinical Trials and their Description 16

Table 6: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine Monotherapy 17 Table 7: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine Monotherapy 18 Table 8: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine in Combination with Eloxatin 22 Table 9: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine in Combination with Cisplatin 23 Table 10: Pancreatic Cancer Therapeutics, Typical Dosing of Teysuno based on Body Surface Area (BSA) of Patient 27 Table 11: Pancreatic Cancer Therapeutics, Adverse Events Associated with Gemcitabine Monotherapy, Teysuno Monotherapy, and with their Combination 27 Table 12: Pancreatic Cancer Therapeutics, Improvements in Overall Survival with Gemcitabine Drug Combinations 29 Read Complete Report with TOC @ http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-showsdiversity-of-novel-targets-though-commercial-impact-remains-distant Table 13: Pancreatic Cancer Therapeutics, Key Molecular Targets of the Developmental Pipeline 42 Table 14: Pancreatic Cancer Therapeutics, Global, Average Clinical Trial Duration (months) 47 Table 15: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine in Combination with Masivet 53 Table 16: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine in Combination with TH-302 57 Table 17: Pancreatic Cancer Therapeutics, Top Five European Markets, Europe Age-Standardized Incidence Rates of Pancreatic Cancer, 2008 75 Table 18: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Discovery Phase 93 Table 19: Pancreatic Cancer Therapeutics, Developmental Pipeline, Preclinical Phase 95 Table 20: Pancreatic Cancer Therapeutics, Developmental Pipeline, IND/CTA-Filed Phase 103 Table 21: Pancreatic Cancer Therapeutics, Developmental Pipeline, Phase I 103 Table 22: Pancreatic Cancer Therapeutics, Developmental Pipeline, Phase II I 105 Table 23: Pancreatic Cancer Therapeutics, Developmental Pipeline, Phase III 110 Table 24: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Pre-Registration 111 Table 25: Pancreatic Cancer Therapeutics, Global, Market Forecast, 2012-2019 111 Table 26: Pancreatic Cancer Therapeutics, US, Market Forecast, 2012-2019 112

Table 27: Pancreatic Cancer Therapeutics, Canada, Market Forecast, 2012-2019 112 Table 28: Pancreatic Cancer Therapeutics, UK, Market Forecast, 2012-2019 113 Table 29: Pancreatic Cancer Therapeutics, France, Market Forecast, 2012-2019 113 Table 30: Pancreatic Cancer Therapeutics, Germany, Market Forecast, 2012-2019 114 Table 31: Pancreatic Cancer Therapeutics, Italy, Market Forecast, 2012-2019 114 Table 32: Pancreatic Cancer Therapeutics, Spain, Market Forecast, 2012-2019 115 Table 33: Pancreatic Cancer Therapeutics, Japan, Market Forecast, 2012-2019 115 Table 34: Pancreatic Cancer Therapeutics, Abbreviations 116 Read Complete Report with TOC @ http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-showsdiversity-of-novel-targets-though-commercial-impact-remains-distant List of Figures Figure 1: Pancreatic Cancer Therapeutics, Global, World-Age Standardized Incidence Rates (rate per 100,000), 2008 10 Figure 2: Pancreatic Cancer Therapeutics, Efficacy Results For Key Parameters - Marketed Products 31 Figure 3: Pancreatic Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products 32 Figure 4: Pancreatic Cancer Therapeutics, Global, Pipeline Distribution by Stage, Program Type and Route of Administration 40 Figure 5: Pancreatic Cancer Therapeutics, Global, Pipeline by Molecule Type and Mechanism of Action 43 Figure 6: Pancreatic Cancer Therapeutics, Global, Pipeline by Molecular Target 46 Figure 7: Pancreatic Cancer Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006-2013 48 Figure 8: Pancreatic Cancer Therapeutics, Global, Clinical Trial Sizes by Phase and Molecule Type, 2006-2013 49 Figure 9: Pancreatic Cancer Therapeutics, Global, Clinical Trial Failure Rate and Reasons for Failure, 2006-2013 50 Figure 10: Pancreatic Cancer Therapeutics, Cross Analysis of Clinical Trial Failure Rate, Duration and Size by Molecule Type and Phase, Global, 2006-2013 52

Figure 11: Pancreatic Cancer Therapeutics, Global, Estimated Sales of TH-302 ($m), 2017-2019 58 Figure 12: Pancreatic Cancer Therapeutics, Global, Estimated Sales of HyperAcute Pancreas ($m), 20152019 60 Figure 13: Pancreatic Cancer Therapeutics, Global, Estimated Sales of MM-398 ($m), 2016-2019 61 Figure 14: Pancreatic Cancer Therapeutics, Efficacy Results for Key Parameters - Pipeline Products 63 Figure 15: Pancreatic Cancer Therapeutics, Safety results for Key Parameters - Pipeline Products 64 Figure 16: Pancreatic Cancer Therapeutics, Product Competitiveness Framework in First-line treatment in Metastatic Disease - Efficacy 65 Figure 17: Pancreatic Cancer Therapeutics, Product Competitiveness Framework in First-line treatment in Metastatic Disease - Safety Parameters 66 Read Complete Report with TOC @ http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-showsdiversity-of-novel-targets-though-commercial-impact-remains-distant Figure 18: Pancreatic Cancer Therapeutics Market, Global, Treatment Patterns and Market Revenues ($m), 2012-2019 69 Figure 19: Pancreatic Cancer Therapeutics, US and Canada, Treatment Usage Patterns, 2012-2019 71 Figure 20: Pancreatic Cancer Therapeutics, US and Canada, Annual Cost of Therapy ($), 2012-2019 72 Figure 21: Pancreatic Cancer Therapeutics Market, US and Canada, Market Revenues ($m), 2012-2019 74 Figure 22: Pancreatic Cancer Therapeutics, Top Five European Markets, Treatment Usage Patterns, 2012-2013 76 Figure 23: Pancreatic Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2012-2019 78 Figure 24: 2019 80

Pancreatic Cancer Therapeutics, Top Five European Markets, Market Revenues ($m), 2012-

Figure 25: Pancreatic Cancer Therapeutics, Japan, Treatment Usage Patterns, 2012-2019 81 Figure 26: Pancreatic Cancer Therapeutics, Japan, Annual Cost of Therapy ($), 2012-2019 82 Figure 27: Pancreatic Cancer Therapeutics, Japan, Market Size ($m), 2012-2019 83 Figure 28: Pancreatic Cancer Therapeutics, Global, Licensing Deals by Region, Value ($m) and Year, 2006-2013 88

Figure 29: Pancreatic Cancer Therapeutics, Global, Licensing Deals by Phase, Value ($m) and Molecule Type, 2006-2013 89 Figure 30: Pancreatic Cancer Therapeutics, Global, Co-Development Deals by Region, Value ($m) and Year, 2006-2013 91 Read Complete Report with TOC @ http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-showsdiversity-of-novel-targets-though-commercial-impact-remains-distant About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit Radiant Insights Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Blog URL: http://radiantinsights.weebly.com/